Medcap: We expect Abilia to recover in Q4 - Nordea

MedCap's flagship company Abilia continues to be negatively impacted by public restrictions, particularly in Norway, although this is partly offset by increased demand in Cardiolex and Inpac. We anticipate that demand for Abilia's product offering will recover when circumstances allow. The restructuring efforts in Specialty Pharma have yet to bear fruit and margins keeps lagging the long-term potential, in our view. We argue that triggers for the share include the realisation of margin potential, further expansion outside the Nordics, and M&A. We increase our DCF-based fair valuation range to SEK 152-178 (147-172) per share following the report.

https://research.nordea.com/CompanyDetails/14559/MedCap

Research feed